Evaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman Syndrome
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Compliance with feeding protocol
Study Overview
Brief Summary
Low carbohydrate diets such as the ketogenic (KD) and low glycemic index (LGIT) diets have been shown to be effective in treating drug resistant seizures in children with Angelman syndrome (AS). The investigators hypothesize that consuming a fat based nutritional formulation with an exogenous ketone throughout the day will produce urinary ketosis in children consuming both low and high carbohydrate diets, depending upon dietary background. The nutritional formulation will provide fuel substrates that push metabolism away from carbohydrates and towards fat utilization. This research is being done to assess the safety and tolerability of a nutritional formulation for use in dietary interventions in AS.
Detailed Description
An evaluation of the safety and tolerability of a nutritional formulation in Angelman syndrome in children ages 4-11 years.
Study is conducted over 16 weeks:
2 week baseline period - Patient continues on current dietary regimen they were on before joining the study (standard, ketogenic, or LGIT).
4 week intervention period - Patient consumes either placebo or nutritional formulation for 4 weeks, maintaining their current diet.
4 week washout period - Patient continues on current dietary regimen without consuming any study formulations.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 4 Years to 11 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female
- •4-11 years of age
- •Diagnosed with Angelman syndrome with prior lab report indicating genetic diagnosis
- •Currently on a LGIT, KD, or standard diet consistently for at least three months
- •Motivated to maintain the LGIT or KD for at least the duration of the trial period, as applicable
- •Written informed consent from patient and/or parent/caregiver
- •Willing to drink provided formulations, or to eat them mixed with food
- •Daytime toilet trained, or parents willing to use cotton balls in diapers to sample urine
- •Willing to test urine daily
- •Willing to comply with protocol examinations, including EEG, ERP, and venipuncture
- •Ambulatory, willing to perform gait tracking
Exclusion Criteria
- •Being pregnant or planning pregnancy
- •Requiring parenteral nutrition
- •Major hepatic or renal dysfunction
- •History of a diagnosis of diabetes
- •Participation in other clinical intervention studies within 1 month prior to entry of this study
- •Allergy to any of the study product ingredients
- •Investigator concern around willingness/ability of patient or parent/caregiver to comply with protocol requirements
- •Any contraindications for the use of the ketogenic or low carbohydrate diets
- •Significantly underweight (Body Mass Index <18.5)
- •Unwilling to drink provided formulations, or to consume formulation mixed with food
- •Not ambulatory, or unwilling to perform gait tracking
- •Not daytime toilet trained, or parents unwilling to use cotton balls in diapers to sample urine
- •Unwilling to test urine daily
Arms & Interventions
Placebo
Subjects assigned to this arm will receive the Placebo Formulation.
Intervention: Placebo Formulation (Dietary Supplement)
Investigational
Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
Intervention: Nutritional Formulation Containing Exogenous Ketones (Dietary Supplement)
Outcomes
Primary Outcomes
Compliance with feeding protocol
Time Frame: 16 weeks
Tolerability will be demonstrated through patient compliance with the protocol as determined by the amount as measured in grams per day of nutritional formulation consumed as compared to the amount prescribed.
Secondary Outcomes
- Number of Patients with Adverse Events(16 weeks (measured 3 times))
- Change in Mobility Measured Using Zeno Walkway(16 weeks (measured 3 times))
- Weight(16 weeks (measured 3 times))
- Convenience, taste, and acceptability(16 weeks (measured 2 times))
- Urinary Ketosis(16 weeks)
- Nutrient Intake(16 weeks)
- Changes in Sleep(16 weeks)
- Changes in Seizures(16 weeks)
- Serum Ketosis(16 weeks (measured 3 times))
- Change in Cognition as Measured by Event Related Potentials (ERP)(16 weeks (measured 3 times))
- Change in Cortical Irritability Measured Using Electroencephalogram (EEG)(16 weeks (measured 3 times))
- Number of Patients with Treatment Related Adverse Events as Assessed by Blood Metabolic Panel(16 weeks (measured 3 times))
- Changes in Gastrointestinal (GI) Health(16 weeks)
- Height(16 weeks (measured 3 times))
- Change from Baseline in the Vineland Adaptive Behavior Score(16 weeks (measured 3 times))